Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Gains pared but markets buoyed by pharma, beverage stocks

Thu, 12th Mar 2015 16:42

UK stocks were off their highest levels of the day by the close on Thursday as mining shares erased earlier gains, though strong performances from pharma and beverage groups provided some support, as well as M&A in the banking sector.The FTSE 100 finished the session up 39.56 points (+0.6%) at 6,761.07, pulling back after hitting a high of 6,799.84 earlier, with concerns about Greece weighing on sentiment in afternoon trade.The European Central Bank (ECB) has reportedly raised its emergency liquidity assistance cap for Greek banks by €600m.Separately, ECB policymaker Jens Weidmann said that Greece has lost a lot of trust and Eurozone governments must figure out whether it is worth the risk of exposure to the country. He added that euro-area's central banks should make sure Greece's banks are careful not to worsen their liquidity position by buying the nation's government debt.Earlier, Greek finance minister Yanis Varoufakis told Mega TV that the ECB is "asphyxiating" the government by its refusal to give Athens any leeway to issue short-term debt to meet its funding needs.In economic data on Thursday, new renminbi loans rose by 1.02bn yuan in February, less than the 1.47bn extended in the prior month but well ahead of the 700bn expected by economists.The UK trade balance registered an unexpectedly large improvement at the start of the year. The deficit on sales of goods overseas shrank to £8.4bn in January from a revised £9.9bn, better than the £9.7bn consensus forecast.Meanwhile, Eurozone industrial production fell 0.1% in January after a 0.3% rise in December, missing the +0.2% estimate.Pharma and beverage stocks buoy marketsShares in Astrazeneca were lifted by comments from UBS which said that upcoming results from the Pegasus study of cardiovascular product Brilinta should drive n "and thus should finally unlock Brilinta's multibillion-dollar potential". The bank said potential upside is "underappreciated" by the market. Sector peer GlaxoSmithKline also rose on plans to sell half of its 12.4% stake in South Africa's largest drug company, Aspen Pharmacare.SABMiller gained after Exane BNP Paribas analysts said "treatment duratioit's now or never for a bid" for the company from Dutch brewing giant Anheuser-Busch InBev. Diageo, meanwhile, was rising after Morgan Stanley initiated coverage on the stock with an 'overweight' rating, saying that its valuation was attractive relative to peers.Shares in recently-floated TSB surged 23% after the company received a £1.7bn bid from Banco Sabadell, helping shares in 50% owner Lloyds higher. A preliminary bid at 340p per share has been tabled, the lender confirmed, 80p higher than its price at flotation last June.Morrisons finished higher despite reporting a £792m loss before tax for the year ending February 2015 as it wrote down the value of its stores by £1.3bn. Like-for-like sales slumped 5.9% for the whole, but the decline eased to just 2.6% by the fourth quarter.Mining stocks erased an earlier rise as metal prices slipped, though Glencore, Rio Tinto and Antofagasta still managed to finish higher. Antofagasta outperformed after reaching an agreement with locals to resolve two-week-long protests that have affected production at its flagship Los Pelambres copper project in Chile.However, BHP Billiton was bucking the trend after going ex-dividend, along with Direct Line, Hargreaves Lansdown, Hammerson, Land Securities, Shire and Standard Chartered.CRH, which is set to buy €6.5bn of assets from European cement giants Holcim and Lafarge as part of their proposed merger, rose strongly after the companies confirmed tie-up talks were continuing, easing recent concerns that the deal could fall apart.Soco International plummeted after the oil and gas group said profits sank to just $14m in 2014 from $104.1m the year before on the back of challenging market conditions.Shares in ASOS soared after the online fashion retailer impressed investors with a strong acceleration in sales growth in the second quarter, helped by a 30% jump in sales in the UK. Market MoverstechMARK 3,167.08 +0.95%FTSE 100 6,761.07 +0.59%FTSE 250 17,061.13 +0.66%FTSE 100 - RisersAstraZeneca (AZN) 4,479.00p +4.05%CRH (CRH) 1,807.00p +3.73%Shire Plc (SHP) 5,455.00p +2.73%Carnival (CCL) 3,097.00p +2.21%Schroders (SDR) 3,195.00p +2.14%GlaxoSmithKline (GSK) 1,548.50p +1.94%Smith & Nephew (SN.) 1,141.00p +1.88%WPP (WPP) 1,548.00p +1.84%Coca-Cola HBC AG (CDI) (CCH) 1,109.00p +1.84%Diageo (DGE) 1,882.00p +1.78%FTSE 100 - FallersStandard Chartered (STAN) 979.00p -4.44%Tullow Oil (TLW) 308.20p -3.26%Direct Line Insurance Group (DLG) 321.00p -2.73%Royal Mail (RMG) 425.80p -2.70%BHP Billiton (BLT) 1,435.50p -2.48%Dixons Carphone (DC.) 429.80p -1.35%Land Securities Group (LAND) 1,198.00p -1.07%ARM Holdings (ARM) 1,162.00p -0.94%Hammerson (HMSO) 649.50p -0.84%Aggreko (AGK) 1,560.00p -0.76%FTSE 250 - RisersTSB Banking Group (TSB) 326.10p +23.48%Thomas Cook Group (TCG) 148.60p +5.09%Hikma Pharmaceuticals (HIK) 2,355.00p +4.99%Cineworld Group (CINE) 467.80p +4.40%Interserve (IRV) 610.00p +4.27%Entertainment One Limited (ETO) 296.70p +4.00%Cairn Energy (CNE) 161.20p +4.00%Supergroup (SGP) 888.50p +3.31%Hunting (HTG) 481.80p +3.26%Henderson Group (HGG) 269.30p +3.14%FTSE 250 - FallersSoco International (SIA) 158.60p -34.46%Serco Group (SRP) 183.70p -11.00%Home Retail Group (HOME) 174.00p -11.00%Balfour Beatty (BBY) 226.70p -2.66%Zoopla Property Group (WI) (ZPLA) 167.30p -2.45%Crest Nicholson Holdings (CRST) 409.20p -2.41%Ted Baker (TED) 2,489.00p -2.39%Brown (N.) Group (BWNG) 331.90p -2.07%Greggs (GRG) 994.00p -1.88%Pace (PIC) 373.60p -1.84%
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.